ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Post-Transplant Anti- A Titer >1:128 in A2-Incompatible Kidney Recipients is Associated with Subclinical Antibody Mediated Rejection

V. Kumar, D. Williams, P. MacLennan, M. Mustian, B. Orandi, L. Williams, J. Locke

University of Alabama at Birmingham, Birmingham, AL

Meeting: 2019 American Transplant Congress

Abstract number: D95

Keywords: Allocation, Antibodies, Kidney transplantation, Rejection

Session Information

Date: Tuesday, June 4, 2019

Session Name: Poster Session D: Kidney Acute Antibody Mediated Rejection

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

Related Abstracts
  • Postoperative Rebound of Anti-Blood Type Antibodies and Antibody-Mediated Rejection After ABO-Incompatible Living Related Kidney Transplantation – Is Prophylactic Treatment Necessary?
  • Minimization of Immunosuppression for ABO-Incompatible Kidney Transplantation Based on the Strength of Pretreatment Anti A/B Antibody Titer

*Purpose: Decreased antigen expression among blood group A, subtype 2 (A2), donor kidneys allows these kidneys to be considered as universal donor kidneys and under the new Kidney Allocation System to be preferentially transplanted into blood group B recipients. Blood group B and O recipients with low titer pre-transplant anti-A antibodies have been shown to have excellent outcomes after A2-incompatible transplantation. However, post-transplant rebound is common, and to date, no study has examined the correlation between this rebound and likelihood of subclinical antibody mediated rejection (AMR).

*Methods: We report 22 ABO incompatible A2/A2B to B/O transplantations with pre transplant anti-A gel titers ≤ 1:64 and daily post-transplant anti-A gel titer monitoring. Immunosuppression consisted of anti-thymocyte globulin induction, tacrolimus, mycophenolate mofetil and prednisone. No patients received pre-transplant conditioning regimen with plasmapheresis. Anti-A titers were measured at baseline and then daily for 14 days after transplantation.

*Results: Median age at transplantation was 50 years. Pre transplant titers were ≤ 1:64 (range 1:2- 1:64). Recipients were predominantly blood type B (B: 59%; O: 41%), male (64%), black race (55%), and received deceased donor kidneys (55%). Titers declined in all patients immediately after transplant and gradually increased during the first post-transplant week. Median time to rebound was 5 days (range 4-6). Median time to peak in gel titers was 10 days (range 9-12 days). There were 3 patients with biopsy proven Banff AMR (>1: thrombotic microangiopathy, glomerulities, and peritubular capillaritis), and none had graft dysfunction at the time of biopsy. Baseline pre-transplant titers did not correlate with AMR; no patients with a rebound titer < 1:128 developed AMR; and 3 out of 6 patients (50%) with anti-A gel titer rebound to > 1:128 developed AMR (Table 1). All 3 patients with biopsy proven subclinical AMR were treated with plasmapheresis, low-dose IVIg, and anti-C5 antibody. No allografts were lost secondary to AMR.

*Conclusions: Rebound in anti-A gel titer to > 1:128 after an A2-incompatible kidney transplantation should prompt a kidney biopsy even in the absence of graft dysfunction to evaluate for subclinical acute AMR. Prompt and aggressive treatment of subclinical AMR should be considered.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Kumar V, Williams D, MacLennan P, Mustian M, Orandi B, Williams L, Locke J. Post-Transplant Anti- A Titer >1:128 in A2-Incompatible Kidney Recipients is Associated with Subclinical Antibody Mediated Rejection [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/post-transplant-anti-a-titer-1128-in-a2-incompatible-kidney-recipients-is-associated-with-subclinical-antibody-mediated-rejection/. Accessed March 6, 2021.

« Back to 2019 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Role of Mitochondria, Metabolism and Inflammation: Pathways Influencing Short Term Outcomes Post-Renal Transplantation
    • Factors Influencing Creatinine Rise Following Donor Nephrectomy

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.